Inovio Pharmaceuticals
INOVIO is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to treat or prevent disease. We have a deep clinical pipeline with multiple potential near- and mid-term catalysts, including a Biologics License Application (BLA) currently under FDA review for lead candidate INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP), a rare HPV-related disease of the respiratory tract, as well as other late stage HPV-related and oncology candi
Basic Information
- Category: Vaccines
- Founded: 1983
- Headquarters: Plymouth Meeting, PA
- Website: inovio.com
Documented Facts
- Email: ino@inovio.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: INO (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Inovio Pharmaceuticals — Official Site (official)
- Inovio Pharmaceuticals on instagram (social)
- Inovio Pharmaceuticals on facebook (social)
- Inovio Pharmaceuticals on linkedin (social)
- INOVIO PHARMACEUTICALS, INC. — SEC EDGAR (reference)
Citation Guidance
Explore Vaccines profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Inovio Pharmaceuticals.
- Canonical profile: https://brandsource.ai/brands/inovio-pharmaceuticals
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/inovio-pharmaceuticals/json-ld
- Citation profile API: https://brandsource.ai/api/brands/inovio-pharmaceuticals/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:04.723Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
INOVIO is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to treat or prevent disease. We have a deep clinical pipeline with multiple potential near- and mid-term catalysts, including a Biologics License Application (BLA) currently under FDA review for lead candidate INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP), a rare HPV-related disease of the respiratory tract, as well as other late stage HPV-related and oncology candi
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 4 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.